

#11/43  
PATENT  
PATENT  
RECEIVED  
10-2-00  
OCT 25 2000

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s) Van Ommen, et al. Examiner: C. Wilder  
Serial No.: 09/445,174 Group Art Unit: 1655  
Filed: April 24, 2000 Docket: 294-78  
For: DIAGNOSTIC TEST KIT FOR Dated: October 18, 2000  
DETERMINING A  
PREDISPOSITION FOR  
BREAST AND OVARIAN  
CANCER, MATERIALS AND  
METHODS FOR SUCH  
DETERMINATION

TECH CENTER 1600/2900  
RECEIVED

OCT 30 2000

TECH CENTER 1600/2900

Assistant Commissioner for Patents  
Washington, DC 20231

*I hereby certify this correspondence is being deposited  
with the United States Postal Service as first class mail,  
postpaid in an envelope, addressed to:  
Assistant Commissioner for Patents, Washington, D.C.*

*20231 on October 18, 2000*

*Dated: 10/18/00*

*Julie L. Watts*

**RESPONSE TO NOTICE TO COMPLY WITH REQUIREMENTS  
FOR PATENT APPLICATION CONTAINING NUCLEOTIDE  
SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES**

Sir:

In response to the Notice to Comply with Requirements for Patent Applications  
Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures mailed  
September 8, 2000, Applicants enclose herewith the following:

1. Diskette containing a substitute Sequence Listing in computer-readable form,  
corrected as directed in the Notice;
2. A substitute paper copy of the "Sequence Listing"; and

3. A copy of the Notice to Comply.

### REMARKS

Applicants have amended the Sequence Listing to conform with the above-referenced Notice to Comply. Entry of the amended Sequence Listing into the specification of the application is respectfully requested.

The Notice to Comply dated September 8, 2000 indicates that the due date for a response to the Notice is the one-month shortened statutory period. This Response is filed within the second month after the September 8, 2000 communication. Accordingly, a Petition for a One Month Extension of Time and the appropriate fee are filed concurrently herewith.

The assignee is a small entity. Therefore, the reduced extension of time fee is being paid. A Declaration Claiming Small Entity is enclosed.


In compliance with the sequence rules as required under 37 C.F.R. §§1.821-1.825, Applicants have amended SEQ. ID NO.: 21 to delete reference to "n". The presence of "n" in the sequence listing was an error. Applicants provide herewith a computer readable form and a paper copy of the corrected Sequence Listing thereby satisfying the requirement under 37 C.F.R. §§1.821 *et seq.*

Under 37 C.F.R. 1.821(f), the Applicants' attorney hereby states that the contents of the computer readable form and the paper copy are the same. Under 37 C.F.R. §1.821(g), the

Applicants' attorney also states that the inclusion of this Sequence Listing does not include any new matter. Accordingly, it is respectfully requested that the Sequence Listing be entered into the application.

If the Examiner has any questions relating to this Amendment or to this application in general, it is respectfully requested that the Examiner contact the Applicants' undersigned attorney at the telephone number provided below.

Respectfully submitted,

  
James F. Harrington  
Registration No. 44,741  
Attorney for Applicants

HOFMANN & BARON, LLP  
6900 Jericho Turnpike  
Syosset, New York 11791  
(516) 822-3550  
JFH:jlw

121195\_1.DOC



UNITED STATES DEPARTMENT OF COMMERCE  
Patent and Trademark Office  
COMMISSIONER OF PATENTS AND TRADEMARKS  
Washington, D.C. 20231

SERIAL NUMBER	FILING DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NO.

EXR.	
Debra Shoemaker	
ART UNIT	PAPER NUMBER

DATE MAILED:

Please find below a communication from the EXR. in charge of this application

Commissioner of Patents

1. The communication filed 7/13/2000 is not fully responsive to the Office communication mailed 6/13/2000 for the reason(s) set forth on the attached Notice To Comply With The Sequence Rules or CRF Diskette Problem Report. Applicant must comply with the requirements of the sequence rules (37 CFR 1.821 - 1.825) before the application can be examined under 35 U.S.C. §§ 131 and 132.

Since the above-mentioned reply appears to be *bona fide* attempt to comply with the requirements of the sequence rules (37 CFR 1.821 - 1.825), applicant is given a TIME PERIOD of **ONE (1) MONTH** from the mailing date of this communication within which to correct the deficiency so as to comply with the sequence rules (37 CFR 1.821 - 1.825) in order to avoid abandonment of the application under 37 CFR 1.821(g). EXTENSIONS OF THIS TIME PERIOD MAY BE GRANTED UNDER 37 CFR 1.136(a).

2. Any inquiry concerning this communication or earlier communications from the Exr. Should be directed to Cynthia Wilder whose telephone number is (703) 305-1680. The Exr. Can normally be reached on Monday-Thursday from 6:30-5:00 pm (Eastern Time).

If attempts to reach the Exr. by telephone are unsuccessful, the Exr.'s supervisor Gary Jones, can be reached at (703) 308-1152. The official fax number for group 1600 is (703) 308-4242, unofficial fax number for group 1600 is (703) 308-8724.

Any inquiry of a general nature or relating to the status of the application should be directed to the groups receptionist whose telephone number is (703) 308-0196.

Cynthia Wilder

Cynthia B. Wilder, PhD  
September 5, 2000

S. Stoner  
[illegible text]

Application No. 09/445,174

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING  
NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES**

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s)

- ☒ 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.
- ☐ 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
- ☐ 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
- ☐ 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
- ☒ 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
- ☐ 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
- ☐ 7. Other: \_\_\_\_\_

**Applicant Must Provide:**

- ☒ An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
- ☐ An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
- ☒ A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216

For CRF Submission Help, call (703) 308-4212

For PatentIn software help, call (703) 308-6856

**PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR RESPONSE**

# RAW SEQUENCE LISTING ERROR REPORT



The Biotechnology Systems Branch of the Scientific and Technical Information Center (STIC) detected errors when processing the following computer readable form:

Application Serial Number 09/445,174

Source: 1655

Date Processed by STIC 7-26-00

RECEIVED

AUG 15

STIC CENTER AUG 2000

**THE ATTACHED PRINTOUT EXPLAINS DETECTED ERRORS.**

**PLEASE FORWARD THIS INFORMATION TO THE APPLICANT BY EITHER:**

- 1) INCLUDING A COPY OF THIS PRINTOUT IN YOUR NEXT COMMUNICATION TO THE APPLICANT, WITH A NOTICE TO COMPLY or,
- 2) TELEPHONING APPLICANT AND FAXING A COPY OF THIS PRINTOUT, WITH A NOTICE TO COMPLY

**FOR FURTHER INFORMATION, PLEASE TELEPHONE MARK SPENCER, 703-308-4212.**

**TO REDUCE ERRORED SEQUENCE LISTINGS, PLEASE USE THE CHECKER VERSION 3.0 PROGRAM ACCESSIBLE THROUGH THE U.S. PATENT AND TRADEMARK OFFICE WEBSITE SEE BELOW.**

## **Checker Version 3.0**

The Checker Version 3.0 application is a state-of-the-art Windows based software program employing a logical and intuitive user interface to check whether a sequence listing is in compliance with format and content rules. Checker Version 3.0 works for sequence listings generated for the original version of 37 CFR §§1.821-1.825 effective October 1, 1990 (old rules) and the revised version (new rules) effective July 1, 1998 as well as World Intellectual Property Organization (WIPO) Standard ST.25.

Checker Version 3.0 replaces the previous DOS-based version of Checker, and is Y2K-compliant. Checker allows public users to check sequence listings in Computer Readable form (CRF) before submitting them to the United States Patent and Trademark Office (USPTO). Use of Checker prior to filing the sequence listing is expected to result in fewer errored sequence listings, thus saving time and money.

**Checker Version 3.0 can be downloaded from the USPTO website at the following address:**

**<http://www.uspto.gov/web/offices/pac/checker>**

# Raw Sequence Listing Error Summary

## ERROR DETECTED SUGGESTED CORRECTION

SERIAL NUMBER:

09/445,174

ATTN: NEW RULES CASES: PLEASE DISREGARD ENGLISH "ALPHA" HEADERS, WHICH WERE INSERTED BY PTO SOFTWARE

RECEIVED

AUG 16 2000

TECH CENTER 160Q/2900

- 1 ☐ Wrapped Nucleics The number/text at the end of each line "wrapped" down to the next line.  
This may occur if your file was retrieved in a word processor after creating it.  
Please adjust your right margin to .3, as this will prevent "wrapping".
- 2 ☐ Wrapped Aminos The amino acid number/text at the end of each line "wrapped" down to the next line.  
This may occur if your file was retrieved in a word processor after creating it.  
Please adjust your right margin to .3, as this will prevent "wrapping".
- 3 ☐ Incorrect Line Length The rules require that a line not exceed 72 characters in length. This includes spaces.
- 4 ☐ Misaligned Amino Acid Numbering The numbering under each 5th amino acid is misaligned. This may be caused by the use of tabs between the numbering. It is recommended to delete any tabs and use spacing between the numbers.
- 5 ☐ Non-ASCII This file was not saved in ASCII (DOS) text, as required by the Sequence Rules.  
Please ensure your subsequent submission is saved in ASCII text so that it can be processed.
- 6 ☐ Variable Length Sequence(s) ☐ contain n's or Xaa's which represented more than one residue.  
As per the rules, each n or Xaa can only represent a single residue.  
Please present the maximum number of each residue having variable length and indicate in the (ix) feature section that some may be missing.
- 7 ☐ PatentIn ver. 2.0 "bug" A "bug" in PatentIn version 2.0 has caused the <220>-<223> section to be missing from amino acid sequence(s) ☐. Normally, PatentIn would automatically generate this section from the previously coded nucleic acid sequence. Please manually copy the relevant <220>-<223> section to the subsequent amino acid sequence. This applies primarily to the mandatory <220>-<223> sections for Artificial or Unknown sequences.
- 8 ☐ Skipped Sequences (OLD RULES) Sequence(s) ☐ missing. If intentional, please use the following format for each skipped sequence:  
(2) INFORMATION FOR SEQ ID NO:X:  
(i) SEQUENCE CHARACTERISTICS:(Do not insert any headings under "SEQUENCE CHARACTERISTICS")  
(xi) SEQUENCE DESCRIPTION:SEQ ID NO:X:  
This sequence is intentionally skipped  
  
Please also adjust the "(iii) NUMBER OF SEQUENCES:" response to include the skipped sequence(s).
- 9 ☐ Skipped Sequences (NEW RULES) Sequence(s) ☐ missing. If intentional, please use the following format for each skipped sequence.  
<210> sequence id number  
<400> sequence id number  
000
- 10 ☒ Use of n's or Xaa's (NEW RULES) Use of n's and/or Xaa's have been detected in the Sequence Listing.  
Use of <220> to <223> is MANDATORY if n's or Xaa's are present.  
In <220> to <223> section, please explain location of n or Xaa, and which residue n or Xaa represents.
- 11 ☐ Use of <213>Organism (NEW RULES) Sequence(s) ☐ are missing this mandatory field or its response.
- 12 ☐ Use of <220>Feature (NEW RULES) Sequence(s) ☐ are missing the <220>Feature and associated headings.  
Use of <220> to <223> is MANDATORY if <213>ORGANISM is "Artificial" or "Unknown"  
Please explain source of genetic material in <220> to <223> section.  
(See "Federal Register," 6/01/98, Vol. 63, No. 104, pp. 29631-32) (Sec. 1.823 of new Rules)
- 13 ☐ PatentIn ver. 2.0 "bug" Please do not use "Copy to Disk" function of PatentIn version 2.0. This causes a corrupted file, resulting in missing mandatory numeric identifiers and responses (as indicated on raw sequence listing).  
Instead, please use "File Manager" or any other means to copy file to floppy disk.



RAW SEQUENCE LISTING  
PATENT APPLICATION: US/09/445,174

DATE: 07/26/2000  
TIME: 10:17:06

Input Set : A:\115541\_1.txt  
Output Set: N:\CRF3\07262000\I445174.raw

Does Not Comply  
Corrected Diskette Needed

1 <110> APPLICANT: van Ommen, Garrit J.B.  
2 Petrij-Bosch, Anne  
3 Bakker, Egbert  
4 Devilee, Peter  
7 <120> TITLE OF INVENTION: A diagnostic test kit for determining a predisposition  
8 for breast and ovarian cancer, materials and methods  
9 for such determination  
11 <130> FILE REFERENCE: P22163CA00  
13 <140> CURRENT APPLICATION NUMBER: US 09/445,174  
14 <141> CURRENT FILING DATE: 2000-04-24  
16 <150> PRIOR APPLICATION NUMBER: PCT/NL98/00325  
17 <151> PRIOR FILING DATE: 1998-06-03  
19 <150> PRIOR APPLICATION NUMBER: EP 97201700.8  
20 <151> PRIOR FILING DATE: 1997-06-04  
22 <160> NUMBER OF SEQ ID NOS: 23  
24 <170> SOFTWARE: PatentIn Ver. 2.1  
26 <210> SEQ ID NO: 1  
27 <211> LENGTH: 20  
28 <212> TYPE: DNA  
29 <213> ORGANISM: Artificial Sequence  
31 <220> FEATURE:  
32 <223> OTHER INFORMATION: Description of Artificial Sequence: primer forward  
33 for D17S1322  
35 <400> SEQUENCE: 1  
36 ctacgctggg caacaaacga 20  
39 <210> SEQ ID NO: 2  
40 <211> LENGTH: 20  
41 <212> TYPE: DNA  
42 <213> ORGANISM: Artificial Sequence  
44 <220> FEATURE:  
45 <223> OTHER INFORMATION: Description of Artificial Sequence: primer reverse  
46 for D17S1322  
48 <400> SEQUENCE: 2  
49 gcaggaagca ggaatggaac 20  
52 <210> SEQ ID NO: 3  
53 <211> LENGTH: 21  
54 <212> TYPE: DNA  
55 <213> ORGANISM: Artificial Sequence  
57 <220> FEATURE:  
58 <223> OTHER INFORMATION: Description of Artificial Sequence: primer forward  
59 for D17S855  
61 <400> SEQUENCE: 3  
62 ggatggcctt ttagaaagtg g 21  
65 <210> SEQ ID NO: 4  
66 <211> LENGTH: 20  
67 <212> TYPE: DNA  
68 <213> ORGANISM: Artificial Sequence

See P. 5

RAW SEQUENCE LISTING  
PATENT APPLICATION: US/09/445,174

DATE: 07/26/2000  
TIME: 10:17:06

Input Set : A:\115541\_1.txt  
Output Set: N:\CRF3\07262000\I445174.raw

```
70 <220> FEATURE:
71 <223> OTHER INFORMATION: Description of Artificial Sequence: primer reverse
72     for D17S855
74 <400> SEQUENCE: 4
75 acacagactt gtcctactgc      20
78 <210> SEQ ID NO: 5
79 <211> LENGTH: 20
80 <212> TYPE: DNA
81 <213> ORGANISM: Artificial Sequence
83 <220> FEATURE:
84 <223> OTHER INFORMATION: Description of Artificial Sequence: primer forward
85     for D17S1323
87 <400> SEQUENCE: 5
88 taggagatgg attattggtg      20
91 <210> SEQ ID NO: 6
92 <211> LENGTH: 20
93 <212> TYPE: DNA
94 <213> ORGANISM: Artificial Sequence
96 <220> FEATURE:
97 <223> OTHER INFORMATION: Description of Artificial Sequence: primer reverse
98     for D17S1323
100 <400> SEQUENCE: 6
101 aagcaacttt gcaatgagtg      20
104 <210> SEQ ID NO: 7
105 <211> LENGTH: 22
106 <212> TYPE: DNA
107 <213> ORGANISM: Artificial Sequence
109 <220> FEATURE:
110 <223> OTHER INFORMATION: Description of Artificial Sequence: primer forward
111     for first PCR
113 <400> SEQUENCE: 7
114 tcacagtgcg gtgaattgga ag      22
117 <210> SEQ ID NO: 8
118 <211> LENGTH: 24
119 <212> TYPE: DNA
120 <213> ORGANISM: Artificial Sequence
122 <220> FEATURE:
123 <223> OTHER INFORMATION: Description of Artificial Sequence: primer reverse
124     for first PCR
126 <400> SEQUENCE: 8
127 gtagccagga cagtagaagg actg      24
130 <210> SEQ ID NO: 9
131 <211> LENGTH: 22
132 <212> TYPE: DNA
133 <213> ORGANISM: Artificial Sequence
135 <220> FEATURE:
136 <223> OTHER INFORMATION: Description of Artificial Sequence: primer forward
137     for second PCR
139 <400> SEQUENCE: 9
```

Input Set : A:\115541\_1.txt  
Output Set : N:\CRF3\07262000\I445174.raw

```
140 gaagaaagag gaacgggctt gg 22
143 <210> SEQ ID NO: 10
144 <211> LENGTH: 21
145 <212> TYPE: DNA
146 <213> ORGANISM: Artificial Sequence
148 <220> FEATURE:
149 <223> OTHER INFORMATION: Description of Artificial Sequence: primer reverse
150 for second PCR
152 <400> SEQUENCE: 10
153 ggccactttg taagtcatt c 21
156 <210> SEQ ID NO: 11
157 <211> LENGTH: 19
158 <212> TYPE: DNA
159 <213> ORGANISM: Artificial Sequence
161 <220> FEATURE:
162 <223> OTHER INFORMATION: Description of Artificial Sequence: primer forward
164 <400> SEQUENCE: 11 19
165 aaccaccaag gtccaaagc
168 <210> SEQ ID NO: 12
169 <211> LENGTH: 24
170 <212> TYPE: DNA
171 <213> ORGANISM: Artificial Sequence
173 <220> FEATURE:
174 <223> OTHER INFORMATION: Description of Artificial Sequence: primer reverse
176 <400> SEQUENCE: 12
177 gtagccagga cagtagaagg actg 24
180 <210> SEQ ID NO: 13
181 <211> LENGTH: 20
182 <212> TYPE: DNA
183 <213> ORGANISM: Artificial Sequence
185 <220> FEATURE:
186 <223> OTHER INFORMATION: Description of Artificial Sequence: primer reverse
188 <400> SEQUENCE: 13
189 tacgtgggtt caactgaagc 20
192 <210> SEQ ID NO: 14
193 <211> LENGTH: 20
194 <212> TYPE: DNA
195 <213> ORGANISM: Artificial Sequence
197 <220> FEATURE:
198 <223> OTHER INFORMATION: Description of Artificial Sequence: primer forward
200 <400> SEQUENCE: 14 20
201 tccattgag aggtcttgc
204 <210> SEQ ID NO: 15
205 <211> LENGTH: 20
206 <212> TYPE: DNA
207 <213> ORGANISM: Artificial Sequence
209 <220> FEATURE:
210 <223> OTHER INFORMATION: Description of Artificial Sequence: primer reverse
212 <400> SEQUENCE: 15
```

RAW SEQUENCE LISTING  
PATENT APPLICATION: US/09/445,174

DATE: 07/26/2000  
TIME: 10:17:06

Input Set : A:\115541\_1.txt  
Output Set : N:\CRF3\07262000\I445174.raw

```
213 actgtgctac tcaagcacca 20
216 <210> SEQ ID NO: 16
217 <211> LENGTH: 24
218 <212> TYPE: DNA
219 <213> ORGANISM: Artificial Sequence
221 <220> FEATURE:
222 <223> OTHER INFORMATION: Description of Artificial Sequence: primer forward
224 <400> SEQUENCE: 16
225 gaaaaaaaag tacaaccaa tgcc 24
228 <210> SEQ ID NO: 17
229 <211> LENGTH: 24
230 <212> TYPE: DNA
231 <213> ORGANISM: Artificial Sequence
233 <220> FEATURE:
234 <223> OTHER INFORMATION: Description of Artificial Sequence: primer reverse
236 <400> SEQUENCE: 17
237 agcccacttc attagtactg gaac 24
240 <210> SEQ ID NO: 18
241 <211> LENGTH: 24
242 <212> TYPE: DNA
243 <213> ORGANISM: Artificial Sequence
245 <220> FEATURE:
246 <223> OTHER INFORMATION: Description of Artificial Sequence: primer forward
248 <400> SEQUENCE: 18
249 taccctataa gccagaatcc agaa 24
252 <210> SEQ ID NO: 19
253 <211> LENGTH: 21
254 <212> TYPE: DNA
255 <213> ORGANISM: Artificial Sequence
257 <220> FEATURE:
258 <223> OTHER INFORMATION: Description of Artificial Sequence: primer reverse
260 <400> SEQUENCE: 19
261 ggccactttg taagctcatt c 21
264 <210> SEQ ID NO: 20
265 <211> LENGTH: 720
266 <212> TYPE: DNA
267 <213> ORGANISM: Homo sapiens
269 <220> FEATURE:
270 <223> OTHER INFORMATION: /note="Exon 22 of BRCA1 and its flanking intron
271 sequences, pos. 79441-80160"
273 <400> SEQUENCE: 20
274 agaggtcttg ctataagcct tcataccggag agtgtagggt agagggcctg ggttaagtat 60
275 gcagattact gcagtgattt tacatctaaa tgtccatttt agatcaactg gaatggatgg 120
276 tacagctgtg tgggtcttct gtggtgaagg agctttcatc attcaccctt ggcacagtaa 180
277 gtattgggtg ccctgtcaga gagggaggac acaatattct ctctgtgag caagactggc 240
278 acctgtcagt ccctatggat gccctactg tagcctcaga agtcttctct gccacatac 300
279 ctgtgccaaa agactccatc tgtaagggat gggtaaggat ttgagaactg cacatattaa 360
280 atatactgag ggaagacttt ttccctctaa ctctttttcc catatgtccc tccccctcct 420
281 ctctgtgact gccccagcat actgtgtttc aacaaatcat caagaaatga tgggctggag 480
```

RECEIVED  
AUG 16 2000  
TECH CENTER 1600/2900

RAW SEQUENCE LISTING  
PATENT APPLICATION: US/09/445,174

DATE: 07/26/2000  
TIME: 10:17:06

Input Set : A:\115541\_1.txt  
Output Set: N:\CRF3\07262000\I445174.raw

282 gctgggcatg gtggctcatg tctgtaatcc cagcactttg ggaggccgag gcaggtggat 540  
283 cacttgctcag gagtttgaga ccagcctggc caacatgggtg aaaccccatc tgtactaaaa 600  
284 aaaaaaaaaa aaaaagttagc caggcctggt ggagcatgcc tgtaatgcca gctatttggg 660  
285 aagttgaggt gtgagcatcg cttgaacgtg ggaggcagag gttgcagtga gccaagattg 720  
288 <210> SEQ ID NO: 21  
289 <211> LENGTH: 180  
290 <212> TYPE: DNA  
291 <213> ORGANISM: Homo sapiens  
293 <220> FEATURE:  
294 <223> OTHER INFORMATION: /note="Intronic region flanking exon 12, pos.  
295 44423 - 44600"  
297 <400> SEQUENCE: 21  
W--> 298 cctgtaatcc cagcactttg ggaggccgag gcgggaggat catgtg<sup>10</sup> caggagatcc 60  
299 agaccatcct ggctaacacg gtgaaacacc atttctacta aaactacaaa aaattagctg 120  
300 ggcattggtg cgggcgctg taatcccagc tactcaggag gctgaagcag aagaatggct 180  
303 <210> SEQ ID NO: 22  
304 <211> LENGTH: 180  
305 <212> TYPE: DNA  
306 <213> ORGANISM: Homo sapiens  
308 <220> FEATURE:  
309 <223> OTHER INFORMATION: /note="Intronic region flanking exon 13, pos.  
310 48256 - 48436"  
312 <400> SEQUENCE: 22  
313 cctgtaaccc cagcactttg ggaggccaag gcaggcgaat cacctgaggt cgaggagctg 60  
314 agaccagcct gaccaacatg gagaaaccac atctctacta aaactacaaa aaattagccg 120  
315 ggcgtggtg cacatgcctg taatcccagc tacttgggag ctacgggtgcc tggcctagtt 180  
318 <210> SEQ ID NO: 23  
319 <211> LENGTH: 60  
320 <212> TYPE: DNA  
321 <213> ORGANISM: Homo sapiens  
323 <220> FEATURE:  
324 <223> OTHER INFORMATION: /note="Deletion-function fragment"  
326 <400> SEQUENCE: 23  
327 agaccatcct ggctaacacg gtgaaacacc atttctacta aaactacaaa aaattagccg 60

Mandatory features missing  
<221> <222> <223>  
Explain location of  
n's and residues  
they represent.  
See # 10 on  
Error Summary  
Sheet.

RECEIVED  
AUG 16 2000  
TECH CENTER 1600/2000

VERIFICATION SUMMARY

PATENT APPLICATION: US/09/445,174

DATE: 07/26/2000

TIME: 10:17:07

Input Set : A:\115541\_1.txt

Output Set: N:\CRF3\07262000\I445174.raw

L:298 M:258 W: Mandatory Feature missing, <221> not found for SEQ ID#:21  
L:298 M:258 W: Mandatory Feature missing, <222> not found for SEQ ID#:21  
L:298 M:340 W: (46) "n" or "Xaa" used: Feature required, for SEQ ID#:21

RECEIVED  
AUG 16 2000  
TECH CENTER 1600/2900